Genedrive PLCLSE: GDR

Funding award from US Department of Defense

· Issued by Genedrive PLC
RNS Number : 6988S
Epistem Holdings plc
21 March 2016

RNS Press Release

For release: 21 March 2016

Award of Funding for Next Stage of US Department of Defense Programme

to Develop Genedrive® Biohazard Identification Tests

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that the US Department of Defense has awarded $2.9m in funding for the next phase of Epistem's programme to develop a handheld Genedrive® test for biohazard identification.

In August 2015, Epistem announced the first $2.4m phase of the $7.8m programme with the US Department of Defense for the development and manufacture of Genedrive® as a biohazard identification system. The second phase announced today was triggered by successful progress to date and is expected to be largely undertaken during the financial year 2016/17.

David Budd, CEO of Epistem, commented "Today's announcement is a recognition of our team's expertise in developing new assays and marks a further important validation of Genedrive®'s potential  as a highly versatile molecular diagnostic system which can be used outside a central lab setting. The US Department of Defense programme funding increases our overall development capability and our ability to develop Genedrive® to realise its full potential."

- Ends -

For further details please contact:

Epistem Holdings Plc

David Budd: CEO                                                                                                           +44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                                      +44 (0)207 418 8900

Tom Burt

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Laura Thornton

[email protected]

Notes to Editors

Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com

This information is provided by RNS
The company news service from the London Stock Exchange
ENDMSCSESSWFFMSELD

Genedrive PLC on 6ix

Earlier from Genedrive

Later from Genedrive

All Genedrive news releases